 |
|
Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity
Jaeseong Oh, Sojeong Yi, Namyi Gu, Dongseong Shin, Kyung-Sang Yu, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang
Genomics Inform. 2018;16(3):52-58. Published online 2018 Sep 30 DOI: https://doi.org/10.5808/GI.2018.16.3.52
|
|
Citations to this article as recorded by
 Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in healthy subjects
Inyoung Hwang, Sang Chun Ji, Jaeseong Oh, Hyojin Kim, Hyunju Cha, John Kim, Chang‐Seok Lee, Kyung‐Sang Yu, SeungHwan Lee
Alimentary Pharmacology & Therapeutics.2023; 57(7): 763. CrossRef Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication
Jingai Jian, Donglin He, Songyan Gao, Xia Tao, Xin Dong
Pharmaceuticals.2023; 16(11): 1568. CrossRef Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine
Richard D. Beger, Michael A Schmidt, Rima Kaddurah-Daouk
Metabolites.2020; 10(4): 129. CrossRef Lipid A profiling and metabolomics analysis of paired polymyxin-susceptible and -resistant MDR Klebsiella pneumoniae clinical isolates from the same patients before and after colistin treatment
Su Mon Aye, Irene Galani, Mei-Ling Han, Ilias Karaiskos, Darren J Creek, Yan Zhu, Yu-Wei Lin, Tony Velkov, Helen Giamarellou, Jian Li
Journal of Antimicrobial Chemotherapy.2020; 75(10): 2852. CrossRef
|